IsoPSA Test Superior to PSA in Prostate Cancer Detection

The new IsoPSA blood test is superior at detecting prostate cancer than current tests, according to a study published in European Urology.
 
More specifically, IsoPSA more precisely distinguishes cancer from benign conditions and identifies patients with high-risk of disease.
 
Once the IsoPSA is validated, its use may significantly reduce the need for biopsies, in addition to lowering the risk of overdetection and overtreatment of nonlethal prostate cancer.
 
Included in the study were 261 men scheduled for a prostate biopsy at 5 academic and community centers in the United States enrolled between August 2015 and December 2016.
 
“Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,” said lead investigator Eric Klein, MD. “Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.”
 
For the study, investigators directly compared the clinical performance of the IsoPSA test to PSA itself with patients already scheduled for prostate biopsy.
 
The results of the study showed that IsoPSA was significantly superior to PSA in discriminating between prostate cancer and benign conditions, and identifying patients with high-grade disease.
 
The first indication may bolster the use of IsoPSA for screening by primary care physicians, while the second indication may be helpful for urologists in identifying patients who would benefit most from curative intent therapy and other options.
 
“The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,” Dr Klein said.
 
If the IsoPSA test is validated and adopted clinically, it could significantly reduce the rate of unnecessary biopsies by nearly 50%.
 
“Due to its inherent simplicity, requiring only a blood draw and presenting information to the physician in familiar context using a single number––just like PSA itself––we are quite hopeful in IsoPSA’s future utility after further validation studies,” said co-author Mark Stovsky, MD.


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.
Among the most prevalent symptoms of chimeric antigen receptor T-cell therapy is encephalopathy.
Study suggests a possible co-treatment strategy to overcome resistance to Venetoclax in the treatment of chronic lymphocyte leukemia and acute myeloid leukemia.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$